Vaxcyte, Inc.
825 Industrial Road, Suite 300
San Carlos
CA
94070
United States
Tel: (650) 837-0111
Website: https://vaxcyte.com/
Email: info@Vaxcyte.com
About Vaxcyte, Inc.
Vaxcyte, Inc. (Nasdaq: PCVX) is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent some of the most common and deadly infectious diseases worldwide. Our exclusively licensed cell-free protein synthesis platform and our proprietary know how enable us to design and produce optimized protein carriers and antigens, the critical building blocks of vaccines, in ways that we believe conventional vaccine technologies cannot. Our lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Our pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease.
65 articles with Vaxcyte, Inc.
-
Vaxcyte to Present at the Jefferies Virtual Healthcare Conference
5/27/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that Company management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:00pm ET.
-
Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal DiseaseVAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte’s Technology Platform
5/10/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the publication of preclinical data supporting the potential of VAX-24, its lead vaccine candidate, in the journal Vaccine
-
Vaxcyte to Present at BofA Securities 2021 Health Care Conference
5/6/2021
Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, announced that Company management will present at the BofA Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 3:30pm ET.
-
Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference
4/5/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 20 th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m. ET.
-
Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/29/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.
-
In a stunning fall from grace playing out this week, former Operation Warp Speed vaccine czar, Dr. Moncef Slaoui, issued a statement Thursday morning, as news emerged that he has resigned from additional biotech posts.
-
Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021
3/22/2021
Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that it will report financial results for the fourth quarter and full year 2020 after market close on March 29, 2021
-
Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections
1/6/2021
Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the publication of preclinical data for VAX-A1, the Company’s novel Group A Streptococcus (Group A Strep) conjugate vaccine candidate, in the journal Infectious Microbes & Diseases . Group A Strep is
-
Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference
11/24/2020
Vaxcyte, Inc. announced that company management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on Wednesday, December 2, 2020 at 1:50pm ET.
-
Vaxcyte to Present at Jefferies Virtual London Healthcare Conference
11/10/2020
Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will present at the Jefferies Virtual London Healthcare Conference on Tuesday November 17, 2020 at 12:35pm ET. A live webcast of the presentation can be a
-
Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update
8/12/2020
Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, announced financial results for the second quarter ended June 30, 2020 and provided a business update.
-
Vaxcyte Appoints Halley E. Gilbert to Board of Directors
6/3/2020
Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the appointment of Halley E. Gilbert to its board of directors. “We’re excited to welcome Halley to Vaxcyte’s board of directors,” said Grant Pickering, Chief Executive Officer an
-
SutroVax Announces Name Change to Vaxcyte
5/21/2020
SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. “We are committed to developing superior vaccines that provide broader protection than what is available c
-
SutroVax Appoints Andrew Guggenhime as Chief Financial Officer and Chief Business Officer
5/4/2020
SutroVax , a biopharmaceutical company dedicated to the development of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the appointment of Andrew Guggenhime as Chief Financial Officer and Chief Business Officer. In this role, Mr. Guggenhime
-
SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
3/26/2020
SutroVax , a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of a $110 million Series D preferred stock financing, co-led by new investors RA Capital Management and Jan
-
The company’s lead vaccine candidate, SVX-24, is a preclinical, 24-valent pneumococcal conjugate vaccine.
-
BioSpace Movers and Shakers, Jan. 31
1/31/2020
Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers. -
SutroVax Announces Executive Appointment
1/30/2020
SutroVax, a biopharmaceutical company dedicated to developing best-in-class conjugate vaccines and novel complex antigen-based vaccines designed to prevent serious infectious diseases, today announced the appointment of Jim Wassil, MS, MBA as Chief Operating Officer
-
SutroVax Receives CARB-X Award for Up to $15 Million to Develop a Universal Vaccine to Prevent Group A Streptococcus Infections
9/3/2019
SutroVax, Inc., today announced it has received an award from CARB-X for up to $15 million in non-dilutive funding to develop a universal vaccine to prevent infections caused by Group A Strep bacteria, which include pharyngitis, impetigo, and necrotizing fasciitis.
-
SutroVax Announces $85M Series C Financing led by TPG Growth
6/7/2018
Provides growth capital to advance pneumococcal vaccine to clinic and beyond